ECSP10010310A - Nuevos compuestos y composiciones y métodos de uso - Google Patents
Nuevos compuestos y composiciones y métodos de usoInfo
- Publication number
- ECSP10010310A ECSP10010310A EC2010010310A ECSP10010310A ECSP10010310A EC SP10010310 A ECSP10010310 A EC SP10010310A EC 2010010310 A EC2010010310 A EC 2010010310A EC SP10010310 A ECSP10010310 A EC SP10010310A EC SP10010310 A ECSP10010310 A EC SP10010310A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- compositions
- new compounds
- uric acid
- acid levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
Abstract
En la presente se describen compuestos útiles en la modulación de los niveles de ácido úrico sanguíneos, formulaciones que los contienen y métodos de uso de los mismos. En algunas realizaciones, los compuestos descritos en la presente se utilizan en el tratamiento o prevención de trastornos relacionados a niveles anormales de ácido úrico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99057407P | 2007-11-27 | 2007-11-27 | |
US9438808P | 2008-09-04 | 2008-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010310A true ECSP10010310A (es) | 2010-07-30 |
Family
ID=40679222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010310A ECSP10010310A (es) | 2007-11-27 | 2010-06-25 | Nuevos compuestos y composiciones y métodos de uso |
Country Status (36)
Country | Link |
---|---|
US (8) | US8084483B2 (es) |
EP (2) | EP2217577B1 (es) |
JP (3) | JP5099794B2 (es) |
KR (2) | KR101291643B1 (es) |
CN (3) | CN102643241B (es) |
AR (1) | AR069753A1 (es) |
AU (2) | AU2008329673C1 (es) |
BR (1) | BRPI0819847B1 (es) |
CA (1) | CA2706858C (es) |
CL (1) | CL2008003529A1 (es) |
CY (1) | CY2019010I2 (es) |
DK (1) | DK2217577T3 (es) |
EA (2) | EA201270666A1 (es) |
EC (1) | ECSP10010310A (es) |
ES (1) | ES2513390T3 (es) |
HK (2) | HK1172326A1 (es) |
HR (1) | HRP20140950T1 (es) |
HU (1) | HUS1900009I1 (es) |
IL (1) | IL205974A (es) |
LT (1) | LTPA2019003I1 (es) |
LU (1) | LUC00103I2 (es) |
MA (1) | MA31936B1 (es) |
ME (2) | ME01294B (es) |
MX (1) | MX2010005776A (es) |
MY (1) | MY147370A (es) |
NO (1) | NO2016016I1 (es) |
NZ (4) | NZ601786A (es) |
PL (1) | PL2217577T3 (es) |
PT (1) | PT2217577E (es) |
RS (1) | RS53569B1 (es) |
SG (1) | SG183721A1 (es) |
SI (1) | SI2217577T1 (es) |
TN (1) | TN2010000237A1 (es) |
TW (1) | TWI415840B (es) |
WO (1) | WO2009070740A2 (es) |
ZA (1) | ZA201003769B (es) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
SG155246A1 (en) | 2004-08-25 | 2009-09-30 | Ardea Biosciences Inc | S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
TWI415840B (zh) * | 2007-11-27 | 2013-11-21 | Ardea Biosciences Inc | 新穎化合物、組合物及使用方法 |
US8242154B2 (en) * | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
JP2012502050A (ja) * | 2008-09-04 | 2012-01-26 | アルディア バイオサイエンス,インク. | 尿酸値を調節するための化合物、組成物及びそれを使用する方法。 |
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
US20110244049A1 (en) * | 2008-10-24 | 2011-10-06 | Ardea Biosciences Inc. | Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof, and methods for preparing and using same |
WO2010048592A1 (en) * | 2008-10-24 | 2010-04-29 | Ardea Biosciences, Inc. | Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US20120122780A1 (en) * | 2009-05-20 | 2012-05-17 | Ardea Biosciences Inc. | Compounds, Compositions and Methods for Modulating Uric Acid Levels |
WO2010135536A2 (en) | 2009-05-20 | 2010-11-25 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
SG182404A1 (en) * | 2010-01-08 | 2012-08-30 | Ardea Biosciences Inc | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof |
WO2011126852A2 (en) * | 2010-03-30 | 2011-10-13 | Ardea Biosciences, Inc. | Treatment of gout |
ES2670700T3 (es) * | 2010-06-15 | 2018-05-31 | Ardea Biosciences, Inc. | Tratamiento de gota e hiperuricemia |
AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
CA2802692C (en) * | 2010-06-16 | 2016-01-05 | Ardea Biosciences, Inc. | Phenylthioacetate compounds useful as uricosuric agents |
EP2627331A4 (en) * | 2010-10-15 | 2014-03-12 | Ardea Biosciences Inc | METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES |
US20130225830A1 (en) * | 2010-10-28 | 2013-08-29 | Mapi Pharma Limited | Polymorphs of febuxostat |
EA022301B1 (ru) * | 2010-12-30 | 2015-12-30 | Ардеа Биосайнсиз, Инк. | Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение |
WO2012122532A2 (en) * | 2011-03-09 | 2012-09-13 | Biocryst Pharmaceuticals, Inc. | Compositions and methods for treatment of hyperuricemia |
EP2714669B1 (en) * | 2011-05-24 | 2017-04-26 | Ardea Biosciences, Inc. | Hypertension and hyperuricemia |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP6025853B2 (ja) | 2011-11-03 | 2016-11-16 | アルデア バイオサイエンシーズ インク. | 3,4−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物 |
US9023856B2 (en) | 2011-11-04 | 2015-05-05 | Cymabay Therapeutics, Inc. | Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent |
BR112014010693A2 (pt) * | 2011-11-04 | 2020-11-10 | Cymabay Therapeutics, Inc. | uso de um composto para a preparação de uma composição farmacêutica para o tratamento de gota em subpopulações de pacientes |
KR101848121B1 (ko) * | 2011-11-04 | 2018-04-11 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | 통풍 발열의 치료법 |
US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
EP2808018B1 (en) * | 2012-01-27 | 2018-03-14 | Teijin Pharma Limited | Therapeutic agent for diabetes |
AR091651A1 (es) * | 2012-07-03 | 2015-02-18 | Ardea Biosciences Inc | Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico |
WO2014077285A1 (ja) * | 2012-11-14 | 2014-05-22 | 帝人ファーマ株式会社 | ピリジン誘導体 |
CN102973530B (zh) * | 2012-12-14 | 2016-08-03 | 贵州信邦制药股份有限公司 | 一种非布索坦双层肠溶片剂及其制备方法 |
MX362747B (es) | 2013-05-13 | 2019-02-05 | Shanghai hengrui pharmaceutical co ltd | Derivado de ácido cicloalquilo, método de preparación del mismo, y aplicación farmacéutica del mismo. |
WO2014198241A1 (en) * | 2013-06-14 | 2014-12-18 | Sunshine Lake Pharma Co., Ltd. | Thio-1,2,4-triazole derivatives and method for preparing the same |
CN103524440B (zh) * | 2013-10-15 | 2015-09-09 | 苏州鹏旭医药科技有限公司 | 痛风治疗药Lesinurad的制备方法及Lesinurad中间体 |
CN104447589B (zh) * | 2013-11-20 | 2017-01-11 | 广东东阳光药业有限公司 | 一种尿酸调节剂的制备方法及其中间体 |
CN103588716A (zh) * | 2013-11-22 | 2014-02-19 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的新晶型及其制备方法 |
CN103613552A (zh) * | 2013-12-02 | 2014-03-05 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
CA2931430A1 (en) * | 2013-11-22 | 2015-05-28 | Crystal Pharmatech Co., Ltd. | Crystalline forms of lesinurad and its sodium salt |
WO2015095703A1 (en) * | 2013-12-20 | 2015-06-25 | Crystal Pharmatech, Inc. | Novel salts and co-crystals of lesinurad |
CN103626710A (zh) * | 2013-12-20 | 2014-03-12 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的共晶及其制备方法 |
CN103755651A (zh) * | 2013-12-23 | 2014-04-30 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法 |
CN105294585B (zh) * | 2014-07-02 | 2019-02-12 | 成都海创药业有限公司 | 一种治疗痛风的化合物 |
CN104068288B (zh) * | 2014-07-25 | 2016-08-24 | 许伟琦 | 一种防尿路结石的饲料添加剂 |
CN104341362B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104341363B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104327000B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104341364A (zh) * | 2014-10-27 | 2015-02-11 | 张远强 | 三氮唑丙二酸类化合物、其制备方法及用途 |
CN104326994A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104326996A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途 |
CN104326993B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104326998B (zh) * | 2014-10-27 | 2016-08-17 | 张远强 | 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
CN104370841B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 |
CN104370842B (zh) * | 2014-10-27 | 2016-07-13 | 张远强 | 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 |
CN104341365A (zh) * | 2014-10-27 | 2015-02-11 | 张远强 | 卤代三氮唑丙二酸类化合物、其制备方法及用途 |
CN104326995A (zh) * | 2014-10-27 | 2015-02-04 | 张远强 | 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途 |
CN104529848A (zh) * | 2014-11-10 | 2015-04-22 | 安徽万邦医药科技有限公司 | 一种1-环丙基-4-异硫氰酰基萘的合成方法 |
EP4349414A2 (en) | 2014-12-23 | 2024-04-10 | Dyve Biosciences, Inc. | Methods and formulations for transdermal administration |
CN107108478B (zh) * | 2014-12-29 | 2020-04-24 | 日本化学药品株式会社 | Urat1抑制剂 |
CN109053608A (zh) * | 2015-02-17 | 2018-12-21 | 华润赛科药业有限责任公司 | 一种旋光纯的硫代乙酸类化合物、其药物组合物和用途 |
CN105622531A (zh) | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | 轴手性异构体及其制备方法和制药用途 |
CN104710374A (zh) * | 2015-04-14 | 2015-06-17 | 安徽省逸欣铭医药科技有限公司 | 一种痛风新化合物及制备方法、用途及其药物制剂 |
CN106187926B (zh) | 2015-04-30 | 2018-11-27 | 天津药物研究院有限公司 | 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
WO2016203436A1 (en) * | 2015-06-19 | 2016-12-22 | Dr. Reddy's Laboratories Limited | Amorphous and amorphous solid dispersion of lesinurad and their preparation |
EP3112334A1 (en) | 2015-06-29 | 2017-01-04 | DPx Fine Chemicals Austria GmbH & CoKG | Process for manufacturing 1-cyclopropyl-naphthalenes |
CN104987311A (zh) * | 2015-06-30 | 2015-10-21 | 安徽万邦医药科技有限公司 | 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯 |
CN105153056A (zh) * | 2015-07-01 | 2015-12-16 | 安徽万邦医药科技有限公司 | 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法 |
CN105017168A (zh) * | 2015-07-01 | 2015-11-04 | 安徽万邦医药科技有限公司 | 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法 |
BR112018002648B1 (pt) * | 2015-08-26 | 2024-01-09 | Stagen Co., Ltd | Intensificador da atp intracelular humana ou animal |
WO2017036884A1 (en) | 2015-08-28 | 2017-03-09 | Sandoz Ag | A lesinurad, free form / lesinurad ethyl ester co-crystal |
CN105301126B (zh) * | 2015-10-10 | 2021-02-12 | 大道隆达(北京)医药科技发展有限公司 | 一种托匹司他有关物质的分析方法 |
US10626096B2 (en) | 2015-11-24 | 2020-04-21 | Sanford Burnham Prebys Medical Discovery Institute | Azole derivatives as apelin receptor agonist |
JP6898330B2 (ja) * | 2015-12-28 | 2021-07-07 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | インドリジン誘導体、組成物、及び使用方法 |
WO2017147270A1 (en) * | 2016-02-24 | 2017-08-31 | Ardea Biosciences, Inc. | Atropisomers of triazole derivative |
CN107176930B (zh) * | 2016-03-11 | 2020-12-01 | 广东赛烽医药科技有限公司 | 2-[5-溴-4-(4-氟代环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基]乙酸化合物及其应用 |
CN107337649B (zh) * | 2016-04-29 | 2020-10-16 | 四川科伦药物研究院有限公司 | 一种乙酸钠水合物无定型及其制备方法和用途 |
AU2017270858B2 (en) | 2016-05-23 | 2019-09-19 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
CN106074540B (zh) * | 2016-06-10 | 2018-10-16 | 江西博屾医疗器械有限公司 | 一种用于高尿酸血症治疗的药物组合物及其应用 |
CN105943552A (zh) * | 2016-06-17 | 2016-09-21 | 王枝宝 | 一种氢氧化钾的医药用途 |
DK3473617T3 (da) * | 2016-06-17 | 2022-11-28 | Medshine Discovery Inc | Halogeneret forbindelse og aksiale, chirale isomerer deraf |
CN106083847B (zh) * | 2016-08-03 | 2018-10-30 | 山东大学 | 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用 |
EP3281941B1 (en) | 2016-08-11 | 2019-07-24 | Zentiva K.S. | Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid |
CZ2016611A3 (cs) * | 2016-09-30 | 2018-05-09 | Zentiva, K.S. | Způsob výroby 2-(5-brom-4-(1-cyklopropylnaftalen-4-yl)-4H-1,2,4-triazol-3-ylthio)octové kyseliny - lesinuradu |
CN108014108A (zh) * | 2016-11-03 | 2018-05-11 | 江苏万邦生化医药股份有限公司 | lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用 |
US10513500B2 (en) | 2016-11-10 | 2019-12-24 | Apotex Inc. | Crystalline forms of Lesinurad |
CN110121359A (zh) | 2016-11-11 | 2019-08-13 | 怀特黑德生物制剂研究所 | 人血浆培养基 |
CN108164471B (zh) * | 2016-12-07 | 2019-09-13 | 浙江京新药业股份有限公司 | Lesinurad衍生物及其制备方法和用途 |
US10351537B2 (en) | 2017-03-10 | 2019-07-16 | Apotex Inc. | Processes for the preparation of lesinurad and intermediates thereof |
EP3315494A1 (en) | 2017-04-19 | 2018-05-02 | Química Sintética, S.A. | Amorphous form of lesinurad and processes for its preparation |
CN108947919B (zh) * | 2017-05-17 | 2023-05-02 | 上海奥博生物医药股份有限公司 | 一种抗痛风药Lesinurad的新型制备方法及其关键中间体 |
WO2018218250A2 (en) * | 2017-05-26 | 2018-11-29 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
US20190083386A1 (en) * | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
CN111386268B (zh) | 2017-11-23 | 2022-04-19 | 东宝紫星(杭州)生物医药有限公司 | 一种urat1抑制剂的晶型及其制备方法 |
EP3498697A1 (en) | 2017-12-12 | 2019-06-19 | Química Sintética, S.A. | Novel salts and polymorphs of lesinurad |
DK3725781T3 (da) | 2017-12-15 | 2022-12-19 | Medshine Discovery Inc | Krystal og salt af 4-(naphthalen-1-yl)-4H-1,2,4-triazol-forbindelse og fremgangsmåde til fremstilling deraf |
CN109369783B (zh) * | 2018-11-30 | 2021-09-10 | 昆明医科大学 | 一种多肽rdp1及其提纯方法与应用 |
CN111320588B (zh) * | 2018-12-14 | 2024-02-09 | 上海奥博生物医药股份有限公司 | 一种纯化Lesinurad的方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2006101A (en) | 1932-07-05 | 1935-06-25 | Meaf Mach En Apparaten Fab Nv | Reversing mechanism for dry gas meters |
US4198513A (en) * | 1970-09-25 | 1980-04-15 | Merck & Co., Inc. | 1,2,4-Triazoles |
NL7112373A (es) * | 1970-09-25 | 1972-03-28 | ||
JPS5641637B2 (es) | 1973-11-26 | 1981-09-29 | ||
US4889868A (en) | 1984-12-20 | 1989-12-26 | Rorer Pharmaceutical Corporation | Bis-imidazolinoamino derivatives as antiallergy compounds |
US5260322A (en) * | 1990-10-08 | 1993-11-09 | Merck & Co., Inc. | Angiotension II antagonists in the treatment of hyperuricemia |
US6832996B2 (en) * | 1995-06-07 | 2004-12-21 | Arthrocare Corporation | Electrosurgical systems and methods for treating tissue |
JPH07215940A (ja) | 1994-01-27 | 1995-08-15 | Torii Yakuhin Kk | 抗ウイルス活性を有する化合物 |
WO1995029897A1 (en) | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
US6017925A (en) | 1997-01-17 | 2000-01-25 | Merck & Co., Inc. | Integrin antagonists |
WO1998035957A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
US6245817B1 (en) * | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
DE69943247D1 (de) * | 1998-03-27 | 2011-04-14 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
BR9915129A (pt) | 1998-11-12 | 2001-08-07 | Neurocrine Biosciences Inc | Antagonistas do receptor de crf e processos relacionados aos mesmos |
WO2000037471A1 (en) * | 1998-12-23 | 2000-06-29 | Neurogen Corporation | 2-amino-9-alkylpurines: gaba brain receptor ligands |
US6593077B2 (en) * | 1999-03-22 | 2003-07-15 | Special Materials Research And Technology, Inc. | Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate |
US6624194B1 (en) * | 1999-06-04 | 2003-09-23 | Metabolex, Inc. | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
CN1494528A (zh) | 2001-03-02 | 2004-05-05 | ʷ��˿�������ȳ�ķ����˾ | 作为逆转录酶抑制剂的二苯酮 |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
ES2300486T3 (es) * | 2002-01-28 | 2008-06-16 | Fuji Yakuhin Co., Ltd. | Nuevos compuestos de 1,2,4-triazol. |
EP1505968A1 (en) | 2002-05-13 | 2005-02-16 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
CN1697650B (zh) * | 2002-08-23 | 2010-11-10 | 阿迪亚生命科学公司 | 非核苷类逆转录酶抑制剂 |
US7642277B2 (en) * | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
EP1597237B1 (en) | 2003-02-07 | 2016-07-27 | Janssen Pharmaceutica NV | Pyrimidine derivatives for the prevention of HIV infection |
WO2005028479A2 (en) | 2003-09-25 | 2005-03-31 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting purine derivatives |
US20080031901A1 (en) * | 2004-09-24 | 2008-02-07 | Abbott Laboratories | Sustained release monoeximic formulations of opioid and nonopioid analgesics |
WO2005046724A1 (ja) | 2003-11-14 | 2005-05-26 | Human Cell Systems, Inc. | 血管障害や高血圧症の治療・予防剤、及びそのスクリーニング方法 |
MXPA06007054A (es) | 2003-12-19 | 2007-04-17 | Elixir Pharmaceuticals Inc | Metodos para tratar una enfermedad. |
CA2558224A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
CN1934095A (zh) * | 2004-03-08 | 2007-03-21 | 惠氏公司 | 离子通道调节剂 |
CN1997633A (zh) | 2004-05-25 | 2007-07-11 | 麦它波莱克斯股份有限公司 | 作为ppar调节剂的取代的三唑及其制备方法 |
US20060013556A1 (en) | 2004-07-01 | 2006-01-19 | Thomas Poslinski | Commercial information and guide |
WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
SG155246A1 (en) * | 2004-08-25 | 2009-09-30 | Ardea Biosciences Inc | S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
JPWO2007043401A1 (ja) * | 2005-10-07 | 2009-04-16 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
WO2007077042A1 (en) | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
EP2001897A2 (en) | 2006-03-22 | 2008-12-17 | Syndexa Pharmaceuticals Corporation | Compounds and methods for treatment of disorders associated with er stress |
CA2653217A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
AU2007267803B2 (en) | 2006-05-25 | 2011-08-25 | Synta Pharmaceuticals Corp. | Method for treating non-Hodgkin's lymphoma |
AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
CA2675443A1 (en) | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals North America, Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
TWI415840B (zh) | 2007-11-27 | 2013-11-21 | Ardea Biosciences Inc | 新穎化合物、組合物及使用方法 |
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
US8242154B2 (en) | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
WO2010048592A1 (en) | 2008-10-24 | 2010-04-29 | Ardea Biosciences, Inc. | Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
EP2714669B1 (en) | 2011-05-24 | 2017-04-26 | Ardea Biosciences, Inc. | Hypertension and hyperuricemia |
-
2008
- 2008-11-26 TW TW097145842A patent/TWI415840B/zh active
- 2008-11-26 PT PT88539002T patent/PT2217577E/pt unknown
- 2008-11-26 KR KR1020107014127A patent/KR101291643B1/ko active IP Right Grant
- 2008-11-26 EP EP08853900.2A patent/EP2217577B1/en active Active
- 2008-11-26 CN CN201210122406.8A patent/CN102643241B/zh active Active
- 2008-11-26 AU AU2008329673A patent/AU2008329673C1/en active Active
- 2008-11-26 CN CN201210376284.5A patent/CN103058944B/zh active Active
- 2008-11-26 SI SI200831300T patent/SI2217577T1/sl unknown
- 2008-11-26 AR ARP080105142A patent/AR069753A1/es unknown
- 2008-11-26 NZ NZ601786A patent/NZ601786A/en not_active IP Right Cessation
- 2008-11-26 KR KR1020127015154A patent/KR101411806B1/ko active IP Right Grant
- 2008-11-26 US US12/324,764 patent/US8084483B2/en active Active
- 2008-11-26 NZ NZ585583A patent/NZ585583A/en not_active IP Right Cessation
- 2008-11-26 ES ES08853900.2T patent/ES2513390T3/es active Active
- 2008-11-26 CN CN2008801234080A patent/CN101918377A/zh active Pending
- 2008-11-26 EA EA201270666A patent/EA201270666A1/ru unknown
- 2008-11-26 DK DK08853900.2T patent/DK2217577T3/da active
- 2008-11-26 ME MEP-2010-100A patent/ME01294B/me unknown
- 2008-11-26 EP EP14179877.7A patent/EP2842948A1/en not_active Withdrawn
- 2008-11-26 MX MX2010005776A patent/MX2010005776A/es active IP Right Grant
- 2008-11-26 CA CA2706858A patent/CA2706858C/en active Active
- 2008-11-26 NZ NZ601774A patent/NZ601774A/xx not_active IP Right Cessation
- 2008-11-26 PL PL08853900T patent/PL2217577T3/pl unknown
- 2008-11-26 BR BRPI0819847-0A patent/BRPI0819847B1/pt active IP Right Grant
- 2008-11-26 RS RS20140533A patent/RS53569B1/en unknown
- 2008-11-26 JP JP2010536189A patent/JP5099794B2/ja active Active
- 2008-11-26 SG SG2012059663A patent/SG183721A1/en unknown
- 2008-11-26 ME MEP-2014-120A patent/ME01996B/me unknown
- 2008-11-26 WO PCT/US2008/084988 patent/WO2009070740A2/en active Application Filing
- 2008-11-26 EA EA201000897A patent/EA018193B3/ru not_active IP Right Cessation
- 2008-11-26 NZ NZ595035A patent/NZ595035A/xx not_active IP Right Cessation
- 2008-11-27 MY MYPI20084819A patent/MY147370A/en unknown
- 2008-11-27 CL CL2008003529A patent/CL2008003529A1/es unknown
-
2010
- 2010-05-26 IL IL205974A patent/IL205974A/en active IP Right Grant
- 2010-05-26 ZA ZA2010/03769A patent/ZA201003769B/en unknown
- 2010-05-27 TN TN2010000237A patent/TN2010000237A1/fr unknown
- 2010-06-25 EC EC2010010310A patent/ECSP10010310A/es unknown
- 2010-06-25 MA MA32950A patent/MA31936B1/fr unknown
-
2011
- 2011-01-31 HK HK12113097.1A patent/HK1172326A1/xx unknown
- 2011-01-31 HK HK13107698.5A patent/HK1180337A1/xx unknown
- 2011-06-30 US US13/174,568 patent/US8357713B2/en active Active
- 2011-06-30 US US13/174,522 patent/US8283369B2/en active Active
- 2011-06-30 US US13/174,594 patent/US8546437B2/en active Active
-
2012
- 2012-04-18 JP JP2012095094A patent/JP2012184234A/ja active Pending
- 2012-05-29 AU AU2012203172A patent/AU2012203172B2/en active Active
-
2013
- 2013-07-30 US US13/954,730 patent/US20140005136A1/en not_active Abandoned
-
2014
- 2014-07-23 JP JP2014150149A patent/JP5905934B2/ja active Active
- 2014-10-02 HR HRP20140950AT patent/HRP20140950T1/hr unknown
-
2016
- 2016-04-08 US US15/094,166 patent/US20160221970A1/en not_active Abandoned
- 2016-08-17 NO NO2016016C patent/NO2016016I1/no unknown
- 2016-11-22 US US15/358,586 patent/US10183012B2/en active Active
-
2019
- 2019-01-14 US US16/246,833 patent/US20190142805A1/en not_active Abandoned
- 2019-02-04 LT LTPA2019003C patent/LTPA2019003I1/lt unknown
- 2019-02-18 LU LU00103C patent/LUC00103I2/fr unknown
- 2019-02-19 HU HUS1900009C patent/HUS1900009I1/hu unknown
- 2019-02-22 CY CY2019010C patent/CY2019010I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010310A (es) | Nuevos compuestos y composiciones y métodos de uso | |
DOP2012000314A (es) | Compuestos, composiciones de tiocetato y metodos de uso | |
CR20110016A (es) | Compuestos quimicos 251 | |
ECSP099413A (es) | COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO | |
ECSP088152A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
EA201100441A1 (ru) | Соединения для коррекции уровня мочевой кислоты и способы их применения | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
UY29853A1 (es) | Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas- | |
WO2011159840A3 (en) | Phenylthioacetate compounds, compositions and methods of use | |
EA201000098A1 (ru) | Производные хиназолинамида | |
ECSP088221A (es) | Agonistas adrenoreceptores alfa2c | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
CL2011002548A1 (es) | Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica. | |
CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
CR11251A (es) | Depsipeptidos ciclicos y usos de los mismos | |
ECSP088252A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
CR9722A (es) | Derivados de benzilpiperazina y su uso medico | |
CO6331434A2 (es) | Nuevos compuestos | |
GT200600106A (es) | Agentes endoparasiticidas | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
CO6331333A2 (es) | Novedosos derivados de pirazol y triazol para trastornos del metabolismo de acido composiciones farmaceuticas que los contienen | |
UY29630A1 (es) | Metodos y formas de dosificación para reducir los efectos secundarios de compuestos de carbamato | |
CY1116286T1 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
TH132750A (th) | องค์ประกอบดูแลช่องปาก |